Black Stools on Triple Therapy Six Weeks After Stenting
Mrs. L is 79 and takes apixaban 5 mg twice daily for atrial fibrillation, aspirin 81 mg daily, and clopidogrel 75 mg daily. Six weeks ago she had a drug-eluting stent placed in the proximal LAD after an NSTEMI. She weighs 55 kg, creatinine is 1.6 mg/dL, and hemoglobin is 10.2 g/dL, down from 12.0 a year ago. She was hospitalized for a bleeding duodenal ulcer two years ago. In clinic today she reports two days of black stools, fatigue, and new bruising on her forearms. Blood pressure 104/66, heart rate 92. She asks whether she 'still needs all three blood thinners.'
1. Is her apixaban dose correct? Show the criteria and your conclusion.
Read the worked answer
No - she is being overdosed.
Apixaban is reduced to 2.5 mg twice daily when at least two of the following three are present:
| Criterion | Threshold | Mrs. L | Met? |
|---|---|---|---|
| Age | 80 years or older | 79 | No |
| Weight | 60 kg or less | 55 kg | Yes |
| Serum creatinine | 1.5 mg/dL or greater | 1.6 mg/dL | Yes |
Two criteria are met, so the correct dose is 2.5 mg twice daily. She is receiving 5 mg twice daily - double the recommended dose - which plausibly contributes to her bruising, anemia, and current GI bleeding.
Clinical point: dose eligibility is not a one-time decision made at initiation. Weight, renal function, and age change over time. Recalculate at every medication reconciliation rather than carrying forward a dose because 'that's what she's always taken.'
2. How should her antithrombotic regimen be adjusted now, balancing stent protection against bleeding risk? Justify your answer.
Read the worked answer
Drop aspirin; continue clopidogrel plus correctly dosed apixaban.
Reasoning:
- She has AF (needs oral anticoagulation), a drug-eluting stent 6 weeks old (needs a P2Y12 inhibitor), and multiple bleeding risk factors: prior duodenal ulcer, anemia, age, chronic kidney disease, low body weight. Her HAS-BLED score is high.
- Guidelines support time-limited triple therapy after PCI, with aspirin withdrawn early - as early as 1–4 weeks - when bleeding risk is high, converting to dual therapy with an anticoagulant plus a P2Y12 inhibitor.
- Six weeks out with an active GI bleed, continuing aspirin adds bleeding without meaningful additional ischemic protection.
- Clopidogrel must not be stopped. At 6 weeks, a drug-eluting stent is still at meaningful thrombosis risk; clopidogrel is also the appropriate P2Y12 choice here, since prasugrel and ticagrelor carry higher bleeding risk and should be avoided in this profile.
Coordinate the change with cardiology rather than making it in isolation, and document the rationale. The patient's own question - 'do I still need all three?' - has a direct answer: no, and that is a safety improvement, not a compromise.
3. What is your immediate plan for the melena, and which reversal or transfusion decisions are and are not indicated?
Read the worked answer
Immediate plan:
- Assess hemodynamics and orthostatic vitals; establish IV access; stat CBC, coagulation studies, type and screen, iron studies later, and renal function.
- Hold apixaban and aspirin pending evaluation; the clopidogrel decision is made jointly with cardiology.
- Urgent gastroenterology consultation for endoscopy - the diagnostic and therapeutic priority in upper GI bleeding.
- Intravenous proton pump inhibitor; resuscitate with crystalloid.
Transfusion: use a restrictive threshold, transfusing around hemoglobin 7 g/dL - but consider a threshold of about 8 g/dL here because of her recent NSTEMI and ongoing bleeding. Over-transfusion raises thrombotic risk; under-transfusion risks myocardial ischemia.
Reversal: routine reversal is not indicated for a stable patient being evaluated for a treatable ulcer. Reserve andexanet alfa or four-factor prothrombin complex concentrate for life-threatening or uncontrolled hemorrhage, in consultation with hematology and cardiology.
Also: educate her not to stop any medication on her own, and flag the need for GI protection and avoidance of NSAIDs at discharge.